| GR00057-A-1 |
104909134 |
NM_004382 |
CRHR1 |
M-003647-00 |
0.02 |
none |
|
no |
|
Wnt/beta-catenin pathway regulation (1) |
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. |
Tang et al. |
2008 |
18621708 |
Cell line |
HeLa |
Wnt pathway reporter |
Luminescence |
Human siArray siRNA library |
Genome-wide |
siRNA |
Z-score |
> 4 |
Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). |
GR00057-A-2 |
104909134 |
NM_004382 |
CRHR1 |
M-003647-00 |
sp |
none |
|
no |
|
Wnt/beta-catenin pathway regulation (2) |
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. |
Tang et al. |
2008 |
18621708 |
Cell line |
HeLa |
Wnt pathway reporter |
Luminescence |
Human siArray siRNA library |
Genome-wide |
siRNA |
Complex, SP |
Complex criteria |
Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). |
GR00184-A-1 |
104909134 |
NM_004382 |
CRHR1 |
M-003647-00 |
-0.0443694155793191 |
none |
|
no |
|
Self-renewal and pluripotency in human embryonic stem cells (1) |
A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. |
Chia et al. |
2010 |
20953172 |
Cell line |
hESC H1 |
POU5F1 protein expression |
Fluorescence |
SMARTpool siRNA library |
Genome-wide |
siRNA |
Z-score |
< -2 |
|
GR00197-A-1 |
104909134 |
1394 |
CRHR1 |
M-003647-00 |
-0.960498833 |
none |
|
no |
|
Human papillomavirus oncogene expression regulation (1) |
Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. |
Smith et al. |
2010 |
20133580 |
Cell line |
C33A/BE2/18LCR c4 |
HPV18 LCR reporter activity |
Luminescence |
Human siGENOME SMARTpool library |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 |
GR00236-A-1 |
104909134 |
1394 |
CRHR1 |
M-003647-00 |
0.999305081378729 |
none |
|
no |
|
Homologous recombination DNA double-strand break repair (HR-DSBR) (1) |
A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. |
Adamson et al. |
2012 |
22344029 |
Cell line |
DR-U2OS |
(HR-DSBR) DR-GFP reporter and DNA content |
Fluorescence |
Human siGENOME siRNA (G-005000-05) |
Genome-wide |
siRNA |
Relative HR ratio |
< ~0.4 OR > 1.88 |
Cutoff values correspond 2 standard deviations from the screen-wide mean |
GR00240-S-1 |
104909134 |
NM_004382 |
CRHR1 |
M-003647-00 |
-0.12 |
none |
|
yes |
|
TRAIL-induced apoptosis (1) |
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. |
Kranz and Boutros |
2014 |
24442637 |
Cell line |
U251MG |
Viability |
Luminescence |
SMART-pool siRNA |
Genome-wide |
siRNA |
Z-score |
> 4 |
Author-submitted data |
GR00240-S-2 |
104909134 |
NM_004382 |
CRHR1 |
M-003647-00 |
1.59 |
none |
|
no |
Z-score 1.752 |
TRAIL-induced apoptosis (2) |
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. |
Kranz and Boutros |
2014 |
24442637 |
Cell line |
U251MG |
Viability (synthetic lethal) |
Luminescence |
SMART-pool siRNA |
Genome-wide |
siRNA |
Differential score |
> 3.6 AND viability Z-score < 4 |
Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. |
GR00249-S |
104909134 |
1394 |
CRHR1 |
s3510 |
-0.24873 |
Decreased viability |
|
no |
number of cells compared to control (%): 34.23 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
104909134 |
1394 |
CRHR1 |
s3511 |
1.89762 |
Increased vaccinia virus (VACV) infection |
|
no |
number of cells compared to control (%): 63.93 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
104909134 |
1394 |
CRHR1 |
s3512 |
-0.87422 |
none |
|
no |
number of cells compared to control (%): 79.29 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00255-A-1 |
104909134 |
1394 |
CRHR1 |
TRCN0000011294, TRCN0000011295, TRCN0000011296, TRCN0000011297, TRCN0000011298 |
-0.489071269 |
none |
|
|
|
Negative genetic interactions (1) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-2 |
104909134 |
1394 |
CRHR1 |
TRCN0000011294, TRCN0000011295, TRCN0000011296, TRCN0000011297, TRCN0000011298 |
0.039424284 |
none |
|
|
|
Negative genetic interactions (2) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-3 |
104909134 |
1394 |
CRHR1 |
TRCN0000011294, TRCN0000011295, TRCN0000011296, TRCN0000011297, TRCN0000011298 |
-0.37012614 |
none |
|
|
|
Negative genetic interactions (3) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-4 |
104909134 |
1394 |
CRHR1 |
TRCN0000011294, TRCN0000011295, TRCN0000011296, TRCN0000011297, TRCN0000011298 |
-0.304147124 |
none |
|
|
|
Negative genetic interactions (4) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-5 |
104909134 |
1394 |
CRHR1 |
TRCN0000011294, TRCN0000011295, TRCN0000011296, TRCN0000011297, TRCN0000011298 |
0.933396611 |
none |
|
|
|
Negative genetic interactions (5) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -0.8 |
HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00300-A |
104909134 |
|
CRHR1 |
TRCN0000011294, TRCN0000011295, TRCN0000011298, TRCN0000011296, TRCN0000011297 |
0 |
none |
|
|
|
Combinatorial effect with RAF inhibitor PLX4720 |
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. |
Whittaker et al. |
2013 |
23288408 |
Cell line |
A375 |
shRNA abundance |
Sequencing |
TRC |
Genome-wide |
shRNA |
Number of shRNAs ranked Top1000 |
> 2 |
The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. |
GR00343-S |
104909134 |
1394 |
CRHR1 |
TRCN0000011295 |
-0.4875000000000007 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
104909134 |
1394 |
CRHR1 |
TRCN0000011296 |
0.6125000000000007 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
104909134 |
1394 |
CRHR1 |
TRCN0000011294 |
0.6824999999999992 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
104909134 |
1394 |
CRHR1 |
TRCN0000011298 |
1.415000000000001 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
104909134 |
1394 |
CRHR1 |
TRCN0000011297 |
-0.3050000000000015 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |